CD19 and cancer: In a Phase I/II dose escalation clinical trial at MD Anderson Cancer Center (NCT03056339), patients with relapsed or refractory CD19 positive cancers were administered 1 × 105, 1 × 106 or 1 × 107 HLA-mismatched anti-CD19-CAR-NK cells.